Please try another search
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Name | Age | Since | Title |
---|---|---|---|
Kinneret Livnat-Savitzky | 55 | 2000 | Independent Director |
Anat Cohen-Dayag | 55 | 2006 | CEO, President & Director |
Antoni Ribas | 54 | 2013 | Member of Scientific Advisory Board |
Iain B. McInnes | - | 2013 | Member of Scientific Advisory Board |
Howard R. Soule | - | 2013 | Member of Scientific Advisory Board |
Drew Mark Pardoll | - | 2014 | Chairman of Scientific Advisory Board |
Paul J. Sekhri | 64 | 2017 | Independent Chairman of the Board |
Eran Perry | 51 | 2019 | Independent Director |
Miriam Merad | - | 2017 | Member of Scientific Advisory Board |
Sanford S. Zweifach | 66 | 2018 | Independent Director |
Gilead Halevy | 56 | 2018 | Independent Director |
Nils Lonberg | 66 | 2020 | Member of Scientific Advisory Board |
Mathias Hukkelhoven | - | 2022 | Independent Director |
Charles Elliott Sigal | 71 | - | Strategic Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review